NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169625&from=3 CLASS PERIOD: March 4, 2024 to May ...

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission-form/?id=169623&from=3 CLASS ...

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 6,736,841 ordinary shares at a public offering price of $47.50 per share, which includes 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary s ...

Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunitiesUpon completion, the royalty management company will manage royalties and milestone payments from financial collaborations, including Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their valueUpon completion, the biopharma operations company will focus on development and potential commercialization of innovative immunology thera ...

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the ...

项目合作与战略布局 - Alexandria房地产信托公司与礼来公司合作在圣地亚哥托里松林地区开设Lilly Gateway Labs创新中心 提供顶级房地产基础设施 实验室运营和场所打造能力 而礼来公司提供科学专业知识 资源 导师支持及通过其风险投资网络获取资本的途径 包括Alexandria Venture Investments [1][2] - 该实验室是继南旧金山和波士顿之后在美国的第四个站点 目前这些实验室支持超过50种新型治疗方法和平台的开发 旨在帮助入驻公司为全球患者提供变革性治疗方法 [3][7] - 新设施采用模块化实验室空间设计 配备邻近协作区 先进科学设备如显微镜和测序仪 并提供一流运营支持 战略规划以及专用建筑安保和礼宾服务 [5] 公司发展与区域生态 - Alexandria自1994年开始开发圣地亚哥生命科学生态系统 其首个收购物业位于托里松林 现成为One Alexandria Square最新阶段的核心 并作为Lilly Gateway Labs的所在地 [4] - One Alexandria Square巨型园区提供新便利设施 包括即取即用咖啡馆 餐厅 活动草坪 会议场所和步行路径 且毗邻知名研究机构 为租户提供丰富合作机会 [4] - 圣地亚哥站点首批入驻的生物技术公司专注于阿尔茨海默病 帕金森病 心血管疾病 代谢性疾病和肿瘤学领域的研发 [5][7] 市场表现与行业对比 - 过去三个月 Alexandria股价上涨15.4% 同期行业增长率为1.7% 表现出显著超额收益 [6] - 房地产投资信托基金行业中 SL Green和Plymouth Industrial REIT位列更高排名 SLG的2025年FFO每股共识预期在过去三个月上调0.83美元至6.21美元 PLYM的预期在过去两个月上调0.02美元至1.88美元 [9]

PresentationGood morning, and welcome to the Larimar Therapeutics Conference Call. [Operator Instructions] Please be advised this call is being recorded at the company's request, and a replay will be available on the company's website. I would now like to turn the call over to Alexandra Folias of LifeSci Advisors. Please go ahead.Alexandra Folias Thank you, operator, and thank you all for participating in today's conference call. Before we start, I'd like to point out that there is a slide deck that accompa ...

临床试验结果 - 公司公布VELA-1和VELA-2三期试验第16周结果 主要终点采用HiSCR75标准（脓肿和炎性结节计数减少75%且无新增脓肿或引流隧道）[1] - 试验共纳入838名患者 设计采用120mg剂量sonelokimab与安慰剂对照 第16周读取HiSCR75数据[2] - 所有关键终点均达到统计学显著性 p值小于0.001 包括病灶计数和患者报告结局[3] - 第16周时VELA-1试验组HiSCR75应答率为34.8% VELA-2试验组为35.9%[5] - 安慰剂组应答率VELA-1为17.5%（符合历史三期试验13%-18%范围） VELA-2为25.6%（高于预期）[5] 药物疗效表现 - sonelokimab在第4周就显示出统计学显著的HiSCR75应答[3] - 初步分析显示16周后应答持续改善 安慰剂组交叉给药后在20周达到与初始试验组相似应答水平[4] - 两个试验均实现所有关键次要终点的统计学显著性 包括HiSCR50和IHS4-55等病灶计数指标[6] - 约30%患者在两项试验中实现疼痛显著减轻（最严重疼痛NRS评分改善至少3分）[6] - 近60%患者实现DLQI有临床意义的改善（4分或以上） 较对照组高出约20个百分点[7] 安全性及管理层评价 - 药物安全性良好 与既往研究一致 未出现新的安全信号[7] - 首席科学官表示对VELA-2较高安慰剂应答率感到失望 但对sonelokimab在所有终点的一致性表现感到鼓舞[7] 市场反应 - 公司股价单日暴跌超过90% 报收6.18美元[8]

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .In this column, I am going to highlight three of my favorite biotech stocks that are trading under $10.00 a share. First, I am going to put a few caveats in place. One of primary ones are these are stocksBret leads the investing group T ...

U.S. stocks traded mixed midway through trading, with the Dow Jones falling more than 50 points on Monday.The Dow traded down 0.12% to 46,190.92 while the NASDAQ rose 0.40% to 22,574.89. The S&P 500 also rose, gaining, 0.13% to 6,652.27.Check This Out: How To Earn $500 A Month From Lamb Weston Stock Ahead Of Q1 EarningsLeading and Lagging SectorsInformation technology shares jumped by 0.6% on Monday.In trading on Monday, energy stocks fell by 1.9%.Top HeadlineCarnival (NYSE: CCL) reported better-than-expect ...